FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. | 20549 | |
|-------------|------|-------|--|
|-------------|------|-------|--|

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | | |
|--------------------------|--|--|--|--|--|--|--|--|
| OMB Number: 3235-0287 | | | | | | | | |
| Estimated average burden | | | | | | | | |
| hours per response: 0.5 | | | | | | | | |

| | tion 1(b). | nac. See | | Filed | pursua or Se | ection 3 | ection 80(h) o | 16(a) of the Ir | of the Sovertmen | ecuriti nt Cor | es Exchang npany Act o | e Act of f 1940 | f 1934 | | | nours | per re | sponse: | 0.5 |
|--|---|--|---------|---------------------------------|--|---|-------------------|--|-------------------------------------|--|---------------------------|--|-----------|---|--|--|--------------------|--|---------------------------------------|
| Name and Address of Reporting Person* Haddadin Yezan Munther | | | | | 2. Issuer Name and Ticker or Trading Symbol Outlook Therapeutics, Inc. [OTLK] | | | | | | | | | k all app Direc | tionship of Reporti all applicable) Director | | 10% Ov | wner | |
| | , | HERAPEUTICS, | Middle) | | 3. Date of Earliest Transaction (Month/Day/Year) 04/19/2021 | | | | | | | | | below | er (give title | | Other (s below) | вреспу | |
| (Street) MONMO JUNCTIO | OUTH N | | 8852 | | 4. If A | Amendi | ment, | Date o | f Origina | ıl Filed | d (Month/Da | y/Year) | | 6. Indi Line) X | Form | filed by On | e Rep | g (Check A orting Person | on |
| (City) | (S | ate) (Z | Zip) | | | | | | | | | | | | | | | | |
| | | Table | I - No | n-Deriva | tive S | Secui | rities | Acq | uired, | Dis | posed of | , or B | enefic | ially | Own | ed | | | |
| 1. Title of Security (Instr. 3) 2. Transac Date (Month/Da | | | | Execut ay/Year) if any | | Deemed ecution Date, ny onth/Day/Year) | | Transaction [| | 4. Securities Acquired (AD Disposed Of (D) (Instr. 3, 5) | | | | 5. Amount of Securities Beneficially Owned Following | | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership | |
| | | | | | | | | Code | v | Amount | (A) (D) | Pric | e | Reported Transaction(s) (Instr. 3 and 4) | | | | (Instr. 4) | |
| Common Stock 04/ | | | 04/19/2 | /2021 | | | P | | 10,000 | 10,000 A S | | .82 | 32 20,000 | | | D | | | |
| | | Tal | | | | | | | | | osed of, convertib | | | | Owned | t | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | if any | emed ion Date, /Day/Year) | Transaction Code (Instr. 8) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | | rative rities ired r osed) | Expiration Date (Month/Day/Year) | | | 7. Title and Amount of Securities Underlying Derivative Security (Insti 3 and 4) | | 8. Price Derivati Security (Instr. 5) | | 9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4) | у | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) |
| | | | | | | | | Date Exercis | able | Expiration Date | Title | Amount or Number of Shares | r | | | | | | |

Explanation of Responses:

Remarks:

/s/ Lawrence Kenyon, Attorney-in-Fact

04/20/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.